Saltar al contenido
Black Friday — 30% OFFEnvío gratis en pedidos desde 99 €
  1. Inicio
  2. Recuperación y regeneración
  3. ACE-031 1 mg
Recuperación

ACE-031 1 mg

ACE-031 (Ramatercept) is a soluble fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to a human IgG1-Fc region.

Presentación: ACE-031 1 mg.

Seleccione la concentración y el tamaño del envase.

Envase ilustrativo generado con IA.

Presentación
El precio original era: 138,95 €.El precio actual es: 97,27 €.

Disponible bajo solicitud en España

Consulta a un asesor
Un asesor se pone en contacto contigo y la farmacia asociada comprueba si es posible continuar y cómo. Puede ser necesaria una receta válida o una evaluación a través de un servicio de telemedicina autorizado.
  • Farmacia asociada
  • Atención personalizada
  • Entrega discreta
  • Presentación
    ACE-031 1 mg

Envío y entrega

  • Envío habitual en 24 horas tras confirmarse el pago.
  • USPS Regular Shipping · 11,95 € · Aprox. 3–5 días laborables
  • FedEx 2 Days Delivery · 28,99 € · Aprox. 2 días laborables
  • FedEx Overnight Delivery · 40,99 € · Aprox. 1 día laborable

Solo para investigación de laboratorio.

No apto para uso humano o veterinario.

Composición y detalles del producto

Descripción

ACE-031 (Ramatercept) is a soluble fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to a human IgG1-Fc region. By acting as a decoy receptor (‘ligand trap’), it sequesters multiple TGF-β superfamily ligands — myostatin, activin A/B, GDF-11, BMP-9, BMP-10 — preventing their binding to native ACVR2B.

Research applications include broad TGF-β superfamily pathway investigation, myostatin/activin pathway dissection, and ligand trap pharmacology.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Datos moleculares en PubChem

ACE-031 1mg1 vial | KIT (10 vials)

Propiedades

Chemical Formula C133H227N43O33
Synonyms UNII-U8DGS69FVC, Myostatin inhibitory peptide 7, U8DGS69FVC, CHEMBL3410227, Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2, BDBM50071379, ACE-031 Myostatin inhibitory peptide 7
Molar Mass 2956.5 g/mol
CAS Number 1621169-52-5
PubChem CID 118732224
Formatos disponibles 1 vial · KIT (10 vials)
Shelf Life 24 months

Investigación

ACE-031 is a recombinant fusion protein consisting of the extracellular ligand-binding domain of ActRIIB fused to human IgG1-Fc. ActRIIB is the primary type II receptor for multiple TGF-β superfamily members. As a soluble decoy receptor, ACE-031 sequesters myostatin (GDF-8), activin A, activin B, GDF-11, and — critically — BMP-9 and BMP-10. In preclinical rodent and non-human primate models, systemic ACE-031 administration produces significant skeletal muscle mass increases and improvements in contractile function, attributable to broad-spectrum ActRIIB ligand neutralisation. Total serum FSH suppression in ACE-031-treated animals reflects near-maximal activin pathway inhibition and is a pharmacodynamic biomarker used in preclinical dose-response characterisation. The broad ActRIIB ligand trap profile also co-inhibits BMP-9 and BMP-10 — TGF-β superfamily members involved in endothelial cell signalling — making this a relevant consideration in study design when vascular biology endpoints are being monitored. Supplied as lyophilised preparation (1 mg/vial). Independently third-party HPLC-tested; COA available per batch.

FAQ

Why does ACE-031 differ from myostatin-selective inhibitors in research applications?

ACE-031 functions as a soluble ActRIIB ligand trap, binding multiple ActRIIB ligands including myostatin, activins, GDF-11, BMP-9, and BMP-10. This broad ligand-binding profile allows investigation of combined ActRIIB pathway suppression rather than isolated myostatin inhibition.

In contrast, myostatin-selective approaches target GDF-8 specifically, making ACE-031 a valuable tool for studying the integrated contribution of multiple ActRIIB ligands to signalling, tissue regulation, and pathway cross-talk.

How does ACE-031 differ from myostatin-specific antibodies?

ACE-031 acts upstream as a receptor-based ligand trap that sequesters multiple ActRIIB-binding growth factors, whereas myostatin-specific antibodies selectively neutralize GDF-8 alone. This distinction allows researchers to compare broad ActRIIB pathway inhibition with highly selective myostatin blockade and evaluate the biological consequences of each approach across different experimental systems.

What endpoints are commonly evaluated in ACE-031 research?

Common endpoints include skeletal muscle mass, muscle fibre morphology, muscle function measurements, ActRIIB pathway biomarkers, Smad2/3 signalling activity, bone-related signalling markers, and expression of genes regulated by myostatin and activin pathways. These endpoints help characterize the effects of broad ActRIIB ligand sequestration and distinguish pathway-specific from multi-ligand responses.

El precio original era: 138,95 €.El precio actual es: 97,27 €.